#United States #Morristown #Whitehawk Therapeutics #MUC16 #HWK-016

Recent Developments in Gynecologic Cancer Treatment

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company, has recently unveiled promising findings on MUC16 at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting held in San Juan, Puerto Rico. These findings illustrate MUC16 as a highly expressed and clinically relevant target for treating gynecologic cancers, particularly ovarian and endometrial types.

Understanding MUC16

MUC16, a cell-surface glycoprotein, plays a significant role in tumor progression by supporting cell proliferation, metastasis, and immune evasion. Notably, MUC16 is overexpressed in numerous tumor types while exhibiting limited expression in normal tissue. A large-scale RNA analysis has confirmed that MUC16 is stably and highly expressed in both ovarian cancers and the aggressive subtypes of endometrial cancer, including late-stage variants. These insights support the development of the investigational antibody-drug conjugate (ADC), HWK-016, which is currently in Phase 1 trials for advanced ovarian and endometrial cancers.

Key Findings on MUC16

Recent analyses reveal that MUC16 exhibits a robust expression profile in various cancer types:

• - Ovarian Cancer: MUC16 has shown remarkably high, tumor-specific expression levels. Studies have indicated that its mRNA expression aligns with the corresponding MUC16 protein levels measured by immunohistochemistry (IHC). Specifically, it is highly prevalent in high-grade serous ovarian carcinoma (HGSOC), which constitutes approximately 70% of ovarian cancer cases. Importantly, MUC16 maintains stable expression across different disease stages and varying platinum sensitivity levels, hence its relevance in both early- and late-line treatment scenarios.
• - Endometrial Cancer: MUC16 consistency also extends to endometrial cancer, particularly in serous adenocarcinoma, the most aggressive subtype, which accounts for a significant proportion of cancer-related deaths. The investigational data confirms that MUC16 retains high expression levels across various disease stages, indicating its suitability as a target for ADC development.

The Role of HWK-016

Whitehawk's HWK-016 has been engineered to overcome limitations of earlier MUC16-directed therapies that targeted the cleaved extracellular portion of the protein. These previous attempts limited effective tumor delivery due to the protein being shed into circulation. In contrast, HWK-016 aims to target the non-shed, membrane-bound portion of MUC16 using a stable, cleavable linker to deliver a novel topoisomerase I inhibitor payload. This approach promises enhanced delivery and therapeutic effect for patients suffering from advanced stages of ovarian and endometrial cancers. Initial results from the Phase 1 clinical trials are anticipated to be available in the first half of 2027.

Expert Insights

Dr. Kathleen N. Moore, Deputy Director at The Fred and Pamela Buffett Cancer Center, emphasized the significance of the findings, noting the uniform expression levels of MUC16 across various stages of disease and treatment response. This consistency indicates that MUC16-targeted therapies, such as HWK-016, hold considerable promise for managing advanced ovarian and endometrial cancers.

Furthermore, Dr. Margaret Dugan, Chief Medical Officer at Whitehawk Therapeutics, highlighted that the real-world data reinforce MUC16's role as a significant target for gynecological cancers. By utilizing cutting-edge ADC engineering alongside established tumor biology, they are committed to delivering innovative and effective treatment options.

Conclusion

The revelations surrounding MUC16 at the SGO 2026 Annual Meeting mark a critical step forward in the quest for more effective treatments for gynecologic cancers. As the clinical trials for HWK-016 progress, the oncology community watches with anticipation, hopeful that these advancements will translate into better patient outcomes.